Cargando…
Eosinophil Cationic Protein Variation in Patients with Asthma and CRSwNP Treated with Dupilumab
Background: Asthma is a clinical syndrome characterized by recurrent episodes of airway obstruction, bronchial hyperresponsiveness and airway inflammation. Most patients with asthma present a “type 2” (TH2) inflammation. ILC2 and TH2 cells release cytokines IL4, IL-13 and IL-5. CRSwNP is a condition...
Autores principales: | Ledda, Andrea Giovanni, Costanzo, Giulia, Sambugaro, Giada, Caruso, Cristiano, Bullita, Martina, Di Martino, Maria Luisa, Serra, Paolo, Firinu, Davide, Del Giacco, Stefano |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10532820/ https://www.ncbi.nlm.nih.gov/pubmed/37763288 http://dx.doi.org/10.3390/life13091884 |
Ejemplares similares
-
Targeting IL-4 and IL-13 Receptors on Eosinophils in CRSwNP Patients: The Clinical Efficacy of Dupilumab
por: Piazzetta, Giovanna Lucia, et al.
Publicado: (2023) -
Real-life effectiveness of dupilumab in patients with mild to moderate bronchial asthma comorbid with CRSwNP
por: Minagawa, Shunsuke, et al.
Publicado: (2022) -
EUFOREA consensus on biologics for CRSwNP with or without asthma
por: Fokkens, Wytske J., et al.
Publicado: (2019) -
Rapid and Continuing Improvements in Nasal Symptoms with Dupilumab in Patients with Severe CRSwNP
por: Bachert, Claus, et al.
Publicado: (2022) -
Olfaction Recovery following Dupilumab Is Independent of Nasal Polyp Reduction in CRSwNP
por: Cantone, Elena, et al.
Publicado: (2022)